Chemoprevention of hepatocellular carcinoma: Concept, progress and perspectives

Journal of Gastroenterology and Hepatology (Australia)

Volumn 16, Issue 12, 2001, Pages 1329-1335

  Okuno, Masataka ^a   Kojima, Soichi ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY   (Japan)

^b RIKEN   (Japan)

Author keywords

Apoptosis; Cancer prevention; Clonal deletion; Interferon; Retinoid

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; GLYCYRRHIZIC ACID; NIK 333; PLASMA PROTEIN; POLYPRENOIC ACID; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TUMOR MARKER;

ANTIVIRAL ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER NECROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; RECURRENT DISEASE; REVIEW;

EID: 0035702637     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2001.02634.x     Document Type: Review

References (70)

1. Rising incidence of hepatocel-lular carcinoma in the United States
2. Risk factors for the rising rates of primary liver cancer in the United States
3. Increase in primary liver cancer in the UK, 1979-94
4. Trends in primary liver cancer
5. Different clini-copathological features of hepatocellular carcinoma in relation to causative agents
6. A multivariate analysis of risk factors of hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
7. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma
8. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma
9. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma
10. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma
11. Survey and follow-up study of primary liver cancer in Japan
12. High frequency of p16INK4A gene alterations in hepatocellular carcinoma
13. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma
14. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
15. Randomized trial of effects of interferon-alpha on the incidence of hepato-cellular carcinoma in chronic active hepatitis C with cirrhosis
16. Prospective study of chemoprevention of hepatocellular carcinoma with Shosaiko-to (TJ-9)
17. The long term efficacy of glycirrhizin in chronic hepatitis C patients
18. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
19. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma
20. Cytokine therapeutics: Lessons from interferon alpha
21. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
22. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
23. Effect of interferon-alfa on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
24. Relation to interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
25. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
26. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C: A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis
27. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: A retrospective study of 1148 patients
28. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncir-rhotic patients with chronic hepatitis C in Japan
29. The interferon receptors
30. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double-blind, placebo-controlled trial
31. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines
32. Interferon-α delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases
33. The Janus protein tyrosine kinase family and its role in cytokine signaling
34. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN, and IFN-inducible genes
35. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2
36. The role of STATs in transcriptional control and their impact on cellular function
37. Recombinant interferon-a in inoperable hepatocellular carcinoma: A randomized controlled trial
38. A prospective trial of recombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma
39. Randomized controlled trial of interferon treatment for advanced hepato-cellular carcinoma
40. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection
41. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α
42. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
43. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha
44. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: A pilot study
45. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C-related liver cancer
46. Histological improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
47. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice
48. Selective activation of extrathymic T cells in the liver by glycyrrhizin
49. Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus
50. Effects of high dose therapy with stronger neo-minophagen C (SNMC) on hepatic histography in non-A, non-B chronic active hepatitis
51. The long term effi-cacy of glycyrrhizin in chronic hepatitis C patients
52. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC
53. Antitumor activities of vitamin A and its derivatives
54. Reduced retinoid content in hepatocellular carcinoma with special reference to alcohol consumption
55. Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3′-methyl-N,N-dimethyl-4-aminoazobenzene
56. The retinoids receptors
57. A new retinoic acid receptor identified from a hepatocellular carcinoma
58. Functional interaction of nuclear factors EF-C, HNF-4, and RXR α with hepatitis B virus enhancer 1
59. Phosphorylation of retinoid X receptora at serine 260 impairs its metabolism and function in human hepatocellular carcinoma
60. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7
61. Deletion of serum lectin-reactive α-fetoprotein by acyclic retinoid: A potent biomarker in the chemoprevention of second primary hepatoma
62. Clonal deletion, a novel strategy of cancer control that falls between cancer chemoprevention and cancer chemotherapy: A clinical experience in liver cancer
63. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
64. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines
65. Retinoid-induced apoptosis in normal and neoplastic tissues
66. Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic
67. Retinoids in cancer chemoprevention
68. Retinoids and apoptosis: Implications for cancer chemoprevention and therapy
69. Regulation of interferon and retinoic acid-induced cell death activation through thioredoxin reductase